Moderna (MRNA) Non-Current Debt (2025 - 2026)

Moderna's (MRNA) quarterly Non-Current Debt came in at $591.0 million in Q2 2026, little changed quarter-over-quarter from $590.0 million in Q1 2026.

Analysis

Moderna (MRNA) Non-Current Debt (2025 - 2026) Analysis & Trends

Moderna (MRNA) has reported Non-Current Debt for 2 consecutive years, with $591.0 million the latest figure, recorded in Q2 2026.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $591.0 million in Q2 2026; TTM through Jun 2026 was $591.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $590.0 million, changed N/A from the prior year.
Non-Current Debt was $591.0 million for Q2 2026 at Moderna, roughly flat from $590.0 million in the prior quarter.
Over five years, Non-Current Debt peaked at $591.0 million in Q2 2026 and troughed at $590.0 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Amgen	236.37 Bn	222.38 Bn	7.24 Bn	57.30 Bn
2	Gilead Sciences	187.38 Bn	184.12 Bn	6.22 Bn	26.25 Bn
3	Vertex Pharmaceuticals	138.36 Bn	130.51 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	85.09 Bn	77.10 Bn	3.93 Bn	1.99 Bn
5	Argenx Se	63.93 Bn	58.75 Bn	1.37 Bn	-
6	Moderna	58.07 Bn	52.94 Bn	52.00 Mn	591.00 Mn
7	Alnylam Pharmaceuticals	35.59 Bn	32.28 Bn	992.69 Mn	-
8	Biogen	32.63 Bn	31.34 Bn	1.96 Bn	7.29 Bn
9	Insmed	27.57 Bn	26.41 Bn	358.27 Mn	546.77 Mn
10	BioNTech SE	26.24 Bn	12.58 Bn	10.00 Mn	124.95 Mn

Historic Data

Download Data